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Abstract
Background: Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous
lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach.
Here we investigated the concordance between mutations found in the primary tumor and pancreatic juice from the
same patient.
Methods: Amplicon-based targeted deep sequencing was performed on samples from 21 patients with pancreatic
ductal adenocarcinoma (PDAC) who had undergone Whipple’s operation. Mutation profiles were determined in
formalin-fixed sections of the primary tumor and in pancreatic juice sampled from the main pancreatic duct during
surgery.
Results: Using a cut-off of 3% for variant allele frequency, KRAS mutations were detected in 20/21 primary tumors
(95%) and in 15/21 (71%) juice samples. When also considering low-frequency variants, KRAS mutations were found in
20/21 juice samples. Most juice samples exhibited multiple KRAS variants not seen in the primary tumor, and only in 11
cases (52%) did the most abundant variant of the juice correspond to the KRAS mutation detected in the tumor. TP53
mutations were found in 16 tumors (76%) and six juice samples (29%). Among the positive juice samples, only one
exhibited more than a single TP53 mutation. Detection of both KRAS and TP53 mutations was fully concordant in the
primary tumor and juice sample in 7/21 cases (33%).
Conclusions: Pancreatic juice from PDAC patients is rich in KRAS mutations often not seen in the primary tumor and
possibly reflecting precancerous lesions in other regions of the pancreas. The inclusion of TP53 mutation detection and
additional markers must therefore be considered for fully exploiting the clinical potential of pancreatic juice samples in
early cancer detection.
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Background
Despite many recent advances in treatment of malignant
disease, pancreatic cancer remains the most lethal
common solid tumor, with an overall 5-year survival rate
of less than 10% [1]. The predominant histologic form of
pancreatic cancer, ductal adenocarcinoma (PDAC), is bio-
logically aggressive and often develops asymptomatically
in the early course of the disease [2]. Surgical resection is
the only curative option available today. However, current
imaging technology is suboptimal for identifying early-
stage tumors or high-grade precancerous lesions, and no
clinically reliable biomarker test is available for early
disease detection [3]. As a result, most patients diagnosed
with PDAC present with a non-resectable advanced-stage
disease and are left with only palliative treatment options.
Thus, there is a strong need for progress in early detection
and therapeutic approaches to improve patient outcomes
in pancreatic cancer.
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Deep sequencing (also known as next-generation se-
quencing or NGS) of circulating tumor DNA (ctDNA)
in body fluids has emerged as a potential tool for cancer
diagnostics and management [4]. Detection of molecular
alterations in ctDNA isolated from pancreatic juice may
represent a useful clinical test in pancreatic cancer diag-
nostics [5] as this fluid flows through the ductal system
where most precursor lesions of malignant pancreatic
tumors arise [3]. Early disease detection based on
ctDNA should also take into account that the somatic
mutations of PDAC are likely to arise in a certain tem-
poral order because these tumors are considered to de-
velop from defined precursor lesions, the most common
being pancreatic intraepithelial neoplasia (PanIN) [6].
Exome sequencing reveals that many somatic mutations
required for PDAC development, most frequently KRAS
and TP53, are shared among moderate and high-grade
PanINs and adjacent PDAC [7]. Oncogenic KRAS muta-
tions are present in at least 90% of PDAC tumors [8], and
they are likely to arise from early mutational events that
occur in the large majority of low-grade PanINs (PanIN-1)
[6]. Similarly, around 70% of PDAC cases harbor inactivat-
ing TP53 mutations that arise in high-grade PanINs
(PanIN-3) before they progress to invasive adenocarcin-
oma [6, 8]. If these and other mutations commonly
present in pancreatic cancer or high-grade dysplasia could
be reliably detected in pancreatic juice, there might be a
potential to identify individuals with early-stage pancreatic
cancer or carcinoma in situ before these lesions become
visible by imaging. This may provide a window for early
medical intervention and a better chance for survival.
In most reports on mutation analysis in pancreatic juice,
either none or only a small number of matched tissue
specimens were analyzed in parallel [9–14]. One study
from 2008 reported similar mutation profiles between
surgically collected pancreatic duct juice and tumor tis-
sues from PDAC patients, but only three hotspot KRAS
mutations were analyzed [9]. Information about concord-
ance between tumor and juice samples with regard to
TP53 and other mutations associated with PDAC is gener-
ally scarce. Thus, it remains to be firmly established to
which degree the mutations found in pancreatic juice
reflect those present in the primary tumor.
In this study, our aim was to provide a better under-
standing of the clinical potential and challenges in early
malignant disease detection by deep-sequencing-based
mutational analysis of DNA isolated from pancreatic
juice. We evaluated the concordance between KRAS and
TP53 mutation profiles in PDAC tissue and pancreatic
juice sampled from the distal dilated duct during resec-
tion of the primary tumor. We found that pancreatic
juice DNA harbors a panorama of KRAS mutations,
making any diagnostic evaluation based only on this
gene of limited value.
Methods
Collection of human pancreatic cancer specimens
We analyzed formalin-fixed, paraffin-embedded (FFPE)
pancreatic tissue and pancreatic juice samples collected
from 21 patients diagnosed with PDAC (Table 1). All cases
(48% males, mean age: 68 years) had undergone resection
of a pancreatic head tumor by the Whipple procedure at
Haukeland University Hospital, Bergen, Norway between
2006 and 2016. After transection of the pancreas, the juice
sample was collected by cannulating the distal, dilated
duct. The sample was immediately aliquoted and stored at
− 80 °C until use. For confirmation of the PDAC diagnosis,
routine pathology reports were reviewed and tumor
sections re-examined by a pathologist experienced in
gastroenterological diseases. The study was approved by
the Research Ethics Committee of Western Norway and
written consent was obtained from the patients.
DNA isolation and quantification
Routine hematoxylin and eosin (H&E)-stained sections
from FFPE pancreatic tumor samples were assessed for
tumor cellularity by a pathologist. Areas enriched for tumor











1 80–89 3.5 40 10
2 60–69 2.5 45 122b
3 70–79 4.0 45 11
4 50–59 2.5 45 46
5 60–69 3.5 50 26
6 70–79 3.0 35 15
7 70–79 1.5 40 45
8 60–69 3.5 20 9
9 60–69 3.5 50 18
10 60–69 2.5 35 80b
11 50–59 2.0 50 36
12 80–89 2.5 15 19
13 70–79 3.0 50 11
14 70–79 4.0 40 11
15 70–79 4.5 50 23
16 50–59 5.0 70 10b
17 60–69 4.0 60 10
18 60–69 4.0 40 13
19 70–79 5.0 40 35b
20 60–69 2.0 30 29b
21 70–79 4.0 40 27
All patients had a diagnosis of pancreatic ductal carcinoma with the tumor
located in the pancreatic head
aLargest measured dimension
bPatient still alive or lost to follow-up
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cells were identified, followed by scraping off these areas
from three unstained, parallel 10-μm sections. As quality
control, a final parallel 5-μm section was made from the tis-
sue block, H&E-stained and compared with the original
H&E section on which the diagnosis was based.
Tumor DNA was extracted using the QIAamp DNA
FFPE Tissue kit (Qiagen) according to the manufac-
turer’s instructions with the following modifications to
obtain higher DNA yield: Lysis of tissue was performed
with 40 μl proteinase K solution per sample with over-
night incubation at 56 °C. An additional volume of 30 μl
proteinase K was then added and the sample further in-
cubated at 56 °C for 2–4 h. DNA from pancreatic juice
was extracted using the QIAamp DNA Investigator kit
(Qiagen) as described by the manufacturer. DNA sam-
ples extracted from both specimen types were eluted in
Buffer ATE provided in the kits and stored at − 20 °C
until use. DNA concentration was determined on the
Qubit V 3.0 fluorometer using the Qubit dsDNA BR
Assay kit (Thermo Fisher Scientific).
PCR amplification and sanger sequencing
Sequences of primers used for PCR amplification of
KRAS exons 2 and 3, TP53 exons 5–10 and BRAF exon
15 are listed in (Additional file 1: Table S1). Identical
primers were used for subsequent Sanger sequencing
unless otherwise specified. In general, PCR reactions
were run in a total volume of 25 μl with 0.3 μM of each
primer and 2 μl purified DNA using the Multiplex PCR
mix (Qiagen). Q-solution from the kit was added to all
reactions except for KRAS exon 2. The following PCR
program was generally used for amplification: 95 °C for
15min; 38 cycles of 94 °C for 1min, Tm for 90 s and 72 °C
for 90 s; ending with 72 °C for 10min. Tm is the annealing
temperature listed in (Additional file 1: Table S1). For
amplification of TP53 exons 8 and 10, touch-down PCR
was performed for the first 20 three-step cycles with the
annealing step decreasing from 60 °C at 0.2 °C/cycle until
Tm was reached and then maintained for another 20
three-step cycles. PCR products were cleaned up enzymat-
ically using the Illustra ExoProStar 1-step reagent (GE
Healthcare) and sequenced in both directions. A sequen-
cing mix of 10 μl in total with 0.2 μM primer was set up
using the BigDye Terminator Cycle Sequencing kit,
Version 1.1 (Applied Biosystems). The following incuba-
tion program was used: 96 °C for 1min; 25 cycles of 96 °C
for 6 s, 57 °C for 3 s and 60 °C for 4min. Reactions were
cleaned up with the BigDye XTerminator Purification kit
and analyzed on the 3500xL Genetic Analyzer (both Ap-
plied Biosystems).
Deep sequencing and data analysis
Amplicon-based targeted sequencing libraries were gen-
erated from 5 to 20 ng DNA using the TruSight Tumor
15 kit (Illumina) according to the manufacturer’s guide.
This kit contains two separate primer pools to amplify,
by multiplex-PCR, the hotspot or coding regions of
KRAS, TP53 and 13 other genes frequently mutated in
solid tumors (Additional file 2: Table S2). Barcoded li-
braries were purified using magnetic beads provided in
the kit. Each library was quantified using the Qubit
dsDNA assay and checked for quality by agarose gel
electrophoresis. Samples were pooled and paired-end se-
quenced on an Illumina MiSeq or MiniSeq sequencer,
with the PhiX control (Illumina) included in each run.
Bioinformatic analysis of the sequencing reads, including
alignment to the hg19/GRCh37 human reference se-
quence and variant calling, was performed using the
TruSight Tumor 15 pipeline as described in the TruSight
Tumor 15 v1.0 Base Space App Guide [15]. Variants
were filtered out by the pipeline before further evalu-
ation when 1) the variant allele frequency (VAF) was <
3.0%; 2) the read depth at the variant position was
<500x; 3) the quality score of the variant was < 30; 4)
there was a significant strand bias, or 5) there was an
indel occurring within a homopolymer region.
Variants were annotated using the software VariantStu-
dio (Illumina). Synonymous variants were not investigated
further, and neither were variants reported with an allele
frequency ≥ 1% in the European or general population
based on reference databases including the 1000 Genomes
Project, Exome Aggregation Consortium (ExAC) and
Genome Aggregation Database (gnomAD). InterVar [16]
was used to aid interpretation of potential pathogenicity
of variants with reference to the COSMIC and IARC
TP53 cancer mutation databases, and to prediction tools
such as SIFT [17] and PolyPhen [18]. Variants were classi-
fied in accordance with the American College of Medical
Genetics and Genomics guidelines [19]. Variants classified
as pathogenic (class 5), likely pathogenic (class 4), and of
uncertain significance (class 3) were reported if listed in
COSMIC. A detailed interpretation is given in (Additional
file 3: Table S3). For each identified variant, a percentage
VAF was given to denote the variant allele prevalence
among the total number of reads at the variant position.
All reported variants were visually examined using the
Integrative Genomics Viewer (IGV 2.4) [20]. Across all
samples, KRAS codons 12, 13 and 61 were manually eval-
uated using the IGV for potential low-abundance variants
(0.2% ≤VAF < 3.0%). We also manually examined the
TP53 loci in the tumor-juice specimen pairs when a muta-
tion was detected bioinformatically in either one of the
samples. The low-frequency variants are specified in red
text in Tables 2, 3 and 4.
PNA clamp real-time PCR assay
Peptide nucleic acid (PNA) clamp real-time PCR was
performed for independent detection of KRAS exon 2
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mutations in DNA from pancreatic juice (5 μl) as previ-
ously described [21]. This method allows detection of
KRAS codon 12/13 mutations with a sensitivity reaching 1
mutated allele per 104 normal copies [22]. Duplicate reac-
tions were run for each sample on the Mx300P real-time
PCR instrument (Stratagene/Agilent), including also
positive and negative controls. The PNA-clamped PCR
products from samples with an amplification signal for
both duplicate reactions were further analyzed by Sanger
sequencing as described above, using a KRAS exon 2
forward primer designed for sequencing of the PNA-
clamped products (Additional file 1: Table S1).
Statistical analysis
All statistical analyses were conducted in R version 3.5.0
using RStudio version 1.1.423. The R package MXM was
used to perform a permutation test for Pearson’s correl-
ation with 1 million permutations to account for the
small sample size, with the original p-value from a stu-
dent’s t-distribution reported as well as the empirical
p-value from the permutation test. The Mann-Whitney
U test was used to assess the difference in the ctDNA
level between the cases with a TP53 mutation detected
only in the tumor and the cases with the same TP53 mu-
tation detected in both the tumor and the juice samples.
Results
Detection of KRAS mutations in the primary tumor
From our biobank of pancreatic cancer cases [23–25],
we identified 21 patients who fulfilled the following cri-
teria: Whipple’s resection performed due to pancreatic
head tumor, a verified diagnosis of PDAC, diagnostic
FFPE tissue blocks available, and pancreatic juice sample
collected during surgery. Clinical characteristics of these
cases are presented in Table 1.
We first evaluated KRAS mutation status in the pri-
mary tumor by Sanger sequencing, a technique which
has a limited sensitivity for detection of somatic muta-
tions. Twenty samples (95%) were positive (Table 2).
Nineteen of these cases had a mutation in codon 12 and
one case had a codon 61 mutation, whereas mutations
in codon 13 were not detected. The high frequency of
KRAS mutations in our patient cohort is consistent with
published data on PDAC cases when sensitive detection
methods are used [8] and indicated that we had obtained
the desired enrichment of tumor cells by manually dis-
secting regions of interest from the FFPE sections.
KRAS mutation status of the primary tumor was then
determined by amplicon-based targeted deep sequencing
using the Illumina TruSight Tumor 15 panel. For all
cases, the mutation status was in concordance with the
results from Sanger sequencing (Table 2). VAF varied
considerably between cases, from 8.7 to 51.7%. There
was limited correlation between VAF and tumor
cellularity (r = 0.56, p = 0.0097, permutation p = 0.012).
Deep sequencing verified that two cases (#12 and #15)
had indels and not biallelic single nucleotide substitu-
tions, as these alternatives were indistinguishable by
Sanger sequencing. In 3 cases (#12, #14 and #20), an
additional KRAS mutation of minor allele frequency (<
3%) was identified by manual examination of the
sequencing reads through the IGV tool. Deep sequen-
cing also revealed that the only case with wild-type
KRAS (#10) harbored the hotspot mutation p.V600E
(c.1799 T > A) in BRAF exon 15 (Table 2). This mutation
was verified by Sanger sequencing.
Detection of KRAS mutations in pancreatic juice
Next, KRAS mutations in ctDNA were evaluated by deep
sequencing pancreatic juice samples from the 21 cases.
When the standard threshold of VAF ≥ 3% was used, 15
cases (71%) were positive (Table 3). However, multiple
KRAS mutations with VAF below the threshold were
observed in many of the juice samples when manually
examined by using the IGV tool. When taking these
low-frequency variants into account, all samples except
one (#17) were positive for one or more KRAS muta-
tions (Table 3). To distinguish the low-frequency KRAS
mutations from technical artefacts, we validated their
presence by independently determining the KRAS muta-
tion load in pancreatic juice using a PNA clamp
real-time PCR assay (see Methods). The PNA clamp
assay was positive for KRAS exon 2 mutations in the
juice samples from the same 20 cases that had been
determined positive by deep sequencing (Table 3). The
PNA-clamped PCR products were subsequently se-
quenced and careful comparisons of individually identified
KRAS exon 2 mutations revealed a high concordance be-
tween both detection methods with regard to the observed
variants (Table 3). Despite low sensitivity, also direct
Sanger sequencing of pancreatic juice DNA visualized the
presence of multiple KRAS mutations when their frequen-
cies were relatively high (VAF > 5%), such as in cases #7
and #15 (data not shown).
Thus, our results showed that DNA isolated from pan-
creatic juice of the PDAC patients frequently harbored
KRAS mutations, many of which were present at low
concentrations or not detected in the primary tumor.
Overall, the KRAS mutation of the tumor could be ob-
served in the juice DNA in 18 cases (86%) (Table 3).
However, the KRAS mutation identified in the primary
tumor corresponded to the predominating mutation in
the juice to a much lesser degree (11 cases, 52%).
Detection of TP53 mutations in the primary tumor and in
pancreatic juice
Deep sequencing detected a TP53 mutation in the pri-
mary tumor of 16 patients (76%), with VAFs ranging
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from 6.4 to 49.9% (Table 4). These mutations were all
confirmed by Sanger sequencing. The detection rate of
TP53 mutations in our study patients is similar to
previously reported data on PDAC [8]. Most of the iden-
tified mutations were located in the hotspot exons 5–8
(Additional file 3: Table S3) [26].
Deep sequencing of the DNA samples from pancreatic
juice revealed TP53 mutations only in six patients (29%)
when using the 3% VAF threshold (Table 4). In four of
these cases, the mutation was identical in the juice
sample and primary tumor. We examined if there was
an association between ctDNA level and positive TP53
status in the juice samples. The percentage of the pri-
mary tumor-specific KRAS mutation in pancreatic juice
(Table 3) was then used as a surrogate measure of the
amount of ctDNA. We observed that the ctDNA level
was significantly lower (p = 0.045, Mann-Whitney U
test) in those cases where the TP53 mutation of the pri-
mary tumor was not found in the juice (median KRAS
VAF: 0.8%, range: 0–18.6%) than in those four instances
where the TP53 mutation was detected (cases #1, 4, 8,
12; median KRAS VAF: 11.8%, range: 4.0–18.7%).
Table 2 KRAS mutation status in the primary tumors as determined by Sanger and deep sequencing
aLow-abundance KRAS mutations with a variant allele frequency (VAF) < 3% are specified in red color. NM, no mutation
bSample was KRAS-negative. Number of reads refers to KRAS exon 2. The sample harbored a BRAF p.V600E mutation (14.5% VAF, 33228 reads)
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Table 3 KRAS mutation status in the pancreatic juice samples as determined by deep sequencing
aLow-abundance KRAS mutations with a VAF < 3% are specified in red color. NM, no mutation
bNA, not assayed by the PNA clamp method
cKRAS-negative and BRAF-positive tumor. No BRAF p.V600E mutation was detected in the corresponding juice sample (23,266 reads at the locus)
dSample had both c.183A > T and c.183A > C mutations, both corresponding to p.Q61H
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One patient (#3) harbored more than a single TP53
mutation in the juice, and neither of the two detected
mutations were identical to that seen in the primary
tumor. The sixth patient with TP53-positive juice sample
(#15) had a TP53-negative tumor. Altogether, only 8 of
21 cases had exactly the same mutation status (normal
sequence or identical mutation) when primary tumor
and juice were compared (Table 4). When manually
inspecting the deep sequencing data for low-frequency
variants, two additional juice samples (#11 and #18)
Table 4 Concordance of TP53 mutations detected in primary tumor and pancreatic juice by deep sequencing
aLow-abundance TP53 mutations with VAF < 3% are specified in red color. NM, no mutation
bTotal number of sequencing reads at the TP53 mutation locus is listed when the mutation was detected in one sample type but not in the other
cConcordant only if the low-frequency mutation in the juice sample is considered
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were positive for TP53 mutations, both containing the
same variant as the primary tumor.
Overall mutation profiles of KRAS and TP53 in the primary
tumor and pancreatic juice
Sixteen patients (76%) harbored both KRAS and TP53
mutations in their primary tumor whereas four had only
a KRAS mutation. The last case was BRAF-positive and
TP53-negative. Pearson’s correlation analysis confirmed
a positive correlation between the VAF of both KRAS
and TP53 mutations in the primary tumor (r = 0.7, p =
0.0027, permutation p = 0.0048; Fig. 1).
Results from the juice samples were more complicated
with many low-frequency KRAS mutations and fewer
TP53 mutations. A summary with regard to KRAS and
TP53 mutation status for all cases is presented in Fig. 2.
Taken together, parallel analysis of KRAS and TP53 in
the primary tumor and pancreatic juice resulted in
exactly the same mutation status in 7 of 21 cases (33%)
when also concordant TP53 negativity was considered.
No mutation in the 13 other genes covered by the
TruSight Tumor 15 gene panel (Additional file 2: Table
S2) was observed in any case, except for the BRAF mu-
tation detected in the single primary tumor being
KRAS-negative. The juice sample from that case did not
display any BRAF mutation.
Discussion
Here we have characterized the mutation patterns of
KRAS and TP53 in matched pancreatic tumor and juice
samples from 21 PDAC patients, using targeted deep se-
quencing with Sanger sequencing and PNA clamp assay
as complementary methods. We identified multiple
KRAS mutations in the juice DNA from almost all cases
(95%). Most of the KRAS mutations in pancreatic juice
were present at low frequencies (VAF < 3%) and were
not seen in the primary tumor.
Previous mutational analyses have shown that KRAS
mutations are commonly detected in pancreatic juice
sampled from patients with pancreatic cancer [9, 13, 27]
or from persons undergoing screening because they are
considered high-risk subjects [12, 14, 28, 29]. Our obser-
vation of multiple KRAS mutations in most juice
samples is consistent with an earlier report focusing on
three hotspot KRAS mutations of codon 12 in matched
pancreatic juice and tumor specimens [9]. Unlike that
study, our method covered the full spectrum of known
somatic KRAS mutations, occurring in codons 12, 13,
59, 61, 117 and 146 [30], and we demonstrate that the
mutation detected in the primary tumor not necessarily
was the predominating KRAS variant in the patient’s
juice sample. Moreover, when the mutation found in the
Fig. 1 A scatterplot of the variant allele frequency (VAF) of the KRAS
mutations against that of the TP53 mutations detected in the primary
tumors (n = 16). The grey shade represents the 95% confidence
interval of the Pearson’s correlation coefficient r. The p-values are from
a student’s t-distribution test and from an empirical test with 1
million permutations
Fig. 2 Overall KRAS and TP53 mutation profile in matched primary tumor and pancreatic juice samples from PDAC patients. Color coding
indicates relationships between mutations detected in the primary tumor and what was found in the corresponding pancreatic juice. The seven
cases in which the mutation status (positive or negative) was concordant in both sample types and for both genes are marked at the bottom of
the display. For concordance evaluation, only mutations with a detected variant allele frequency (VAF)≥ 3% were considered
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tumor was absent from the juice, other KRAS mutations
were usually present.
Particularly illustrative in this regard is case #10 with a
primary tumor that was BRAF-positive and KRAS-nega-
tive (Table 3). Still, 22.9% of the KRAS exon 3 reads
from the corresponding juice sample displayed the mu-
tation Q61H, whereas BRAF alterations were not de-
tected. An oncogenic BRAF mutation is reported to
occur in 3% of PDAC cases and is most often mutually
exclusive with the presence of a KRAS mutation [31].
This is in line with the finding that dysregulation in the
RAS-RAF-MAPK signaling pathway is a key driver for
PDAC [32]. The absence of the BRAF mutation in the
juice of case #10 suggests that the fluid contained little
DNA arising from the tumor, and that the KRAS
mutation may have its origin somewhere else, most
likely in the tail region of the pancreas drained by the
distal duct.
Accordingly, our observation of multiple, mostly low-
abundance KRAS mutations in pancreatic juice (Table
3), may be explained by the presence of several PanIN
precursor lesions in the gland. Low-grade PanIN lesions
are frequently present in healthy aged individuals [33]
and in PDAC patients [34]. Over 90% of low-grade
PanIN-1 lesions have already acquired a KRAS mutation
[6], but obviously most do not progress to invasive can-
cer. Nevertheless, these lesions may shed DNA and con-
tribute to the pool of cell-free DNA in the juice. In fact,
the presence of more than one KRAS mutation in each
pancreatic juice sample has been reported from older
healthy individuals and patients with pancreatic non-ma-
lignant abnormalities such as chronic pancreatitis and
cysts [9, 12]. These KRAS mutations may dominate over
the tumor-specific mutations, as demonstrated in our
case series. This strongly suggests that the informative
value of detecting KRAS mutations in pancreatic juice
DNA with the purpose of early pancreatic cancer de-
tection or differential diagnostics is limited. It should
be noted, though, that the presence of multiple KRAS
mutations in a pancreatic juice sample also might re-
flect clonal heterogeneity of the primary tumor [8].
Detection of TP53 mutations in combination with KRAS
in pancreatic juice could improve specificity for PDAC, be-
cause somatic alterations in TP53 arise later during tumori-
genesis and is generally present only in high-grade PanIN
lesions [6]. Such mutations are in general absent in
juice samples from healthy individuals and chronic
pancreatitis cases [11]. Thus, with one exception, no
juice sample in our series harbored more than a sin-
gle TP53 mutation. The striking difference between
the KRAS and TP53 mutation distributions lends fur-
ther support to the assumption that the majority of
the multiple KRAS mutations found in pancreatic
juice DNA originate from low-grade PanIN lesions.
The detection rate of TP53 mutations (29%) in the juice
samples of our study is substantially lower than in other
reports studying this biological material from PDAC
patients (around 60%) [11, 13, 14]. However, in those pub-
lications information of the TP53 mutation status of the
primary tumor was lacking for the majority of cases.
Moreover, the pancreatic juice samples stemmed from the
duodenal lumen of PDAC patients who had their tumors
located in all regions of the pancreas [11, 13, 14]. In con-
trast, the juice samples of our study were collected from
the distal pancreatic duct where the fluid had accumulated
due to obstruction imposed by the tumor located in the
pancreatic head. This physical obstruction of the proximal
pancreatic duct could possibly have favored the relative
enrichment of DNA from the distal part of the pancreas
rather than from the tumor. Consistently, we observed
that the amount of ctDNA was low in those cases where a
TP53mutation was detected only in the tumor (when using
the percentage of the tumor-specific KRAS mutation in
pancreatic juice as a surrogate measure for ctDNA level).
Because of their later occurrence during tumorigenesis,
TP53 mutations generally have a frequency that is lower
than or similar to that of KRAS during clonal expansion of
the cancer [35]. Thus, the scarcity of detected TP53 muta-
tions in the juice samples could partly be due to a ctDNA
level below the detection limit and partly due to the fact
that around 30% of PDAC cases lack TP53 point mutations
or small indels [8].
Nevertheless, we found that TP53 mutations were
absent from the majority of the juice samples, even
when the tumor was positive. With reference to the
mutation profile in the primary tumor, we suggest
that analyzing TP53 mutations in combination with
KRAS mutations in the juice might represent a more
specific although, unfortunately, less sensitive test for
PDAC detection.
Our study has several limitations. Firstly, the number
of cases was limited and prevented us from investigating
the relationship between mutation detection (or concen-
tration) and clinico-pathological variables such as patient
survival, cancer stage and tumor differentiation. Secondly,
we employed a commercial deep sequencing panel that was
constructed to cover 15 genes frequently mutated in vari-
ous cancers (Additional file 2: Table S2). For PDAC, this
panel covers only KRAS and TP53 among the frequently
mutated genes in this cancer type. We detected a BRAF
mutation in one case, but otherwise the remaining 12
genes were negative for all specimens tested. Thirdly,
the amplicon-based deep sequencing technology was
not optimized to identify low-abundance mutations in
the juice. The concentration of ctDNA in pancreatic
juice can often be low (VAF < 3%), as shown in our
study. This makes it challenging to reliably detect and
distinguish low-frequency mutations from PCR
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artefacts and sequencing errors inherent in amplicon-
based assays [36].
For KRAS exon 2, we circumvented this issue by using
the highly sensitive PNA clamp technology to comple-
ment and independently identify low-abundance muta-
tions. The results from the PNA clamp assay supported
the deep sequencing results as all samples were positive
except one (#17), which was negative with both tech-
niques. Sanger sequencing of the PNA-clamped products
also confirmed that multiple KRAS mutations were
indeed present in DNA from pancreatic juice. However,
using complementary assays depending on mutation-
specific probes (e.g. PNA clamp assays and droplet
digital PCR) is impractical when a larger set of cancer-
associated genes are to be screened. Strategies such as
digital deep sequencing [13, 14] and molecular barcod-
ing [37] should be implemented in order to better
characterize the mutational load in pancreatic juice in
future follow-up work. Moreover, sampling of duodenal
fluid after secretin stimulation [38] represents a less in-
vasive procedure for obtaining pancreatic juice than
sampling directly from the pancreatic duct and would
therefore be the method of choice when screening pan-
creatic cancer high-risk patients. On the other hand, the
tumor-specific DNA may then be more diluted, as duo-
denal juice also contains DNA (including bacterial
DNA) and fluid from the duodenal lumen [28].
Finally, we note that in the KRAS- and TP53-mutated
primary tumor cases, the allele frequencies of both mu-
tations tended to be similar (Fig. 1), supporting the view
that the two mutations originated from the same tumor
clone. We also found that some patients exhibited KRAS
and/or TP53 mutations at an allele frequency of around
50% in the tumor (e.g. case #16). As stromal and other
non-neoplastic cells will contribute significantly to the
isolated DNA, this suggests an amplification event of the
oncogenic KRAS allele [39] and deletion of the wild-type
TP53 allele [8], respectively. Noteworthy, a subset of
pancreatic cancers manifest genomic instability that
leads to chromosomal alterations including the KRAS
and TP53 loci [40].
Conclusions
Our results show that pancreatic juice DNA from patients
with PDAC is very rich in KRAS mutations. Most of these
mutations were not present in the primary tumor of the
pancreatic head but might reflect somatic mutations
within PanIN lesions in other regions of the organ. This
supports the notion that detection of only KRAS muta-
tions in pancreatic juice samples has limited diagnostic
utility in relation to PDAC. The addition of TP53 muta-
tion detection could result in a more specific test for
PDAC, although with reduced sensitivity. Most likely,
additional genes (such as the frequently mutated CDN
K2A and SMAD4 genes [8]) or biomarkers associated with
pancreatic malignancies (such as DNA methylation [41]
and telomerase activity [42]) must be included to fully ex-
ploit the clinical potential of pancreatic juice samples in
early cancer detection.
Additional files
Additional file 1: Table S1. Primers used for PCR amplification and
Sanger sequencing of KRAS, TP53 and BRAF mutations. (DOCX 21 kb)
Additional file 2: Table S2. List of genes and target regions covered by
the TruSight Tumor 15 gene panel. (DOCX 19 kb)
Additional file 3: Table S3. Interpretation of all KRAS, TP53 and BRAF
mutations observed in the study. (DOCX 37 kb)
Abbreviations
BRAF: Gene encoding B-Raf proto-oncogene serine/threonine kinase;
ctDNA: circulating tumor DNA; FFPE: Formalin-fixed, paraffin-embedded;
H&E: Hematoxylin and eosin; IGV: Integrative Genomics Viewer; KRAS: Gene
encoding Kirsten RAS proto-oncogene GTPase; PanIN: Pancreatic
intraepithelial neoplasia; PDAC: Pancreatic ductal adenocarcinoma;
PNA: Peptide nucleic acid; TP53: Gene encoding tumor suppressor protein
p53; VAF: variant allele frequency
Funding
This study was supported by the Helse Vest Regional Health Authority (PhD
fellowship no. 912143 to MHC and Strategic Grant no. 912009 to RH and
ON). The funding body had no role in the design of the study, or in the
collection, analysis and interpretation of data, or in writing the manuscript.
Availability of data and materials
The deep sequencing data and other data analyzed during the study are
available from the corresponding author on reasonable request.
Authors’ contributions
The study was designed and directed by AM with important contributions
from RH and ON. DH recruited and operated the patients and collected the
pancreatic tissue and juice samples. The experimental work was performed
by MHC and EM-A with assistance of SM, SJS and KT. KEJ helped with pro-
curement and handling of the pancreatic tissue specimens. HAS and SK pro-
vided expertise in pathology and deep sequencing, respectively. The tables
were compiled by MHC and EM-A. MHC made the figures and also drafted
the manuscript together with AM. All authors commented the paper and
approved the final version.
Ethics approval and consent to participate
The study was performed according to the Helsinki Declaration and the
patients had given their written informed consent. Approval of the project





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Gade Laboratory for Pathology, Department of Clinical Medicine, University
of Bergen, Bergen, Norway. 2Department of Pathology, Haukeland University
Hospital, Bergen, Norway. 3Department of Hematology and Oncology,
Choi et al. BMC Cancer           (2019) 19:11 Page 10 of 12
Stavanger University Hospital, Stavanger, Norway. 4Section of Oncology,
Department of Clinical Science, University of Bergen, Bergen, Norway.
5Department of Oncology, Haukeland University Hospital, Bergen, Norway.
6Department of Gastrointestinal Surgery, Haukeland University Hospital,
Bergen, Norway. 7Department of Medical Genetics, Haukeland University
Hospital, Bergen, Norway. 8KG Jebsen Center for Diabetes Research,
Department of Clinical Science, University of Bergen, Bergen, Norway.
Received: 9 August 2018 Accepted: 6 December 2018
References
1. American Cancer Society. 2018. https://www.cancer.org/research/cancer-
facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html.
Accessed November 21st, 2018.
2. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med.
2014;371:1039–49.
3. Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK, et
al. Early detection of sporadic pancreatic cancer: summative review.
Pancreas. 2015;44:693–712.
4. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et
al. Liquid biopsies come of age: towards implementation of circulating
tumour DNA. Nat Rev Cancer. 2017;17:223–38.
5. Lipner MB, Yeh JJ. Sequencing pancreatic juice: squeezing the most out of
surveillance. Clin Cancer Res. 2018.
6. Oldfield LE, Connor AA, Gallinger S. Molecular events in the natural history
of pancreatic cancer. Trends Cancer. 2017;3:336–46.
7. Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, et al. Genetic
alterations associated with progression from pancreatic intraepithelial neoplasia
to invasive pancreatic tumor. Gastroenterology. 2013;145:1098–109 e1.
8. The Cancer Genome Atlas Research Network. Integrated genomic
characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:
185–203.e13.
9. Shi C, Fukushima N, Abe T, Bian Y, Hua L, Wendelburg BJ, et al. Sensitive
and quantitative detection of KRAS2 gene mutations in pancreatic duct
juice differentiates patients with pancreatic cancer from chronic pancreatitis,
potential for early detection. Cancer Biology & Therapy. 2008;7:353–60.
10. Kanda M, Knight S, Topazian M, Syngal S, Farrell J, Lee J, et al. Mutant GNAS
detected in duodenal collections of secretin-stimulated pancreatic juice
indicates the presence or emergence of pancreatic cysts. Gut. 2013;62:1024–33.
11. Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, et al. Mutant
TP53 in duodenal samples of pancreatic juice from patients with pancreatic
cancer or high-grade dysplasia. Clinical Gastroenterology and Hepatology .
2013;11:719–730 e5.
12. Eshleman JR, Norris AL, Sadakari Y, Debeljak M, Borges M, Harrington C, et
al. KRAS and guanine nucleotide-binding protein mutations in pancreatic
juice collected from the duodenum of patients at high risk for neoplasia
undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol. 2015;13:
963–9 e4.
13. Yu J, Sadakari Y, Shindo K, Suenaga M, Brant A, Almario JAN, et al. Digital
next-generation sequencing identifies low-abundance mutations in
pancreatic juice samples collected from the duodenum of patients with
pancreatic cancer and intraductal papillary mucinous neoplasms. Gut. 2017;
66:1677–87.
14. Suenaga M, Yu J, Shindo K, Tamura K, Almario JAN, Zaykoski CM, et al.
Pancreatic juice mutation concentrations can help predict the grade of
dysplasia in patients undergoing pancreatic surveillance. Clin Cancer Res.
2018;24:2963–74.
15. Illumina Support Center. 2018. https://support.illumina.com. Accessed 22
Aug 2018.
16. Li Q, Wang K. InterVar: clinical interpretation of genetic variants by the 2015
ACMG-AMP guidelines. Am J Hum Genet. 2017;100:267–80.
17. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat
Protoc. 2009;4:1073–81.
18. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human
missense mutations using PolyPhen-2. Current Protocols in Human
Genetics. 2013;Chapter 7:Unit7.20.
19. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and Genomics
and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
20. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G,
et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24.
21. Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, et al.
Clinical relevance of circulating KRAS mutated DNA in plasma from patients
with advanced pancreatic cancer. Mol Oncol. 2016;10:635–43.
22. Gilje B, Heikkila R, Oltedal S, Tjensvoll K, Nordgard O. High-fidelity DNA
polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR
assay for K-ras mutations. J Mol Diagn. 2008;10:325–31.
23. Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A. Molecular analysis of
the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of
mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448:788–96.
24. Immervoll H, Hoem D, Steffensen OJ, Miletic H, Molven A. Visualization of
CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas:
non-overlapping membrane expression in cell populations positive for both
markers. J Histochem Cytochem. 2011;59:441–55.
25. El Jellas K, Hoem D, Hagen KG, Kalvenes MB, Aziz S, Steine SJ, et al.
Associations between ABO blood groups and pancreatic ductal
adenocarcinoma: influence on resection status and survival. Cancer
Medicine. 2017;6:1531–40.
26. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al.
Mutations in the p53 gene occur in diverse human tumour types. Nature.
1989;342:705–8.
27. Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T, et al.
Detection of mutations of p53 tumor suppressor gene in pancreatic juice
and its application to diagnosis of patients with pancreatic cancer:
comparison with K-ras mutation. Clin Cancer Res. 1999;5:1147–53.
28. Sadakari Y, Kanda M, Maitani K, Borges M, Canto MI, Goggins M. Mutant
KRAS and GNAS DNA concentrations in secretin-stimulated pancreatic fluid
collected from the pancreatic duct and the duodenal lumen. Clin Transl
Gastroenterol. 2014;5:e62.
29. Suenaga M, Dudley B, Karloski E, Borges M, Irene Canto M, Brand RE, et al.
The effect of pancreatic juice collection time on the detection of KRAS
mutations. Pancreas. 2018;47:35–9.
30. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et al.
Extended RAS gene mutation testing in metastatic colorectal carcinoma to
predict response to anti–epidermal growth factor receptor monoclonal
antibody therapy: American Society of Clinical Oncology provisional clinical
opinion update 2015. J Clin Oncol. 2016;34:179–85.
31. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, et al.
Whole-exome sequencing of pancreatic cancer defines genetic diversity
and therapeutic targets. Nat Commun. 2015;6:6744.
32. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core
signaling pathways in human pancreatic cancers revealed by global
genomic analyses. Science. 2008;321:1801–6.
33. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of
pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases
with and 152 cases without pancreatic ductal adenocarcinoma. Mod
Pathol. 2003;16:996–1006.
34. Laghi L, Orbetegli O, Bianchi P, Zerbi A, Di Carlo V, Boland CR, et al.
Common occurrence of multiple K-RAS mutations in pancreatic cancers
with associated precursor lesions and in biliary cancers. Oncogene. 2002;
21:4301–6.
35. Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and
genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553.
36. Schirmer M, Ijaz UZ, D'Amore R, Hall N, Sloan WT, Quince C. Insight into
biases and sequencing errors for amplicon sequencing with the Illumina
MiSeq platform. Nucleic Acids Res. 2015;43:e37.
37. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and
quantification of rare mutations with massively parallel sequencing. Proc
Natl Acad Sci. 2011;108:9530–5.
38. Erchinger F, Engjom T, Tjora E, Hoem D, Hausken T, Gilja OH, et al.
Quantification of pancreatic function using a clinically feasible short
endoscopic secretin test. Pancreas. 2013;42:1101–6.
39. Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, et
al. Evolutionary routes and KRAS dosage define pancreatic cancer
phenotypes. Nature. 2018;554:62–8.
40. Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, et al. A
renewed model of pancreatic cancer evolution based on genomic
rearrangement patterns. Nature. 2016;538:378–82.
Choi et al. BMC Cancer           (2019) 19:11 Page 11 of 12
41. Yokoyama S, Kitamoto S, Higashi M, Goto Y, Hara T, Ikebe D, et al. Diagnosis
of pancreatic neoplasms using a novel method of DNA methylation analysis
of mucin expression in pancreatic juice. PLoS One. 2014;9:e93760.
42. Hata T, Ishida M, Motoi F, Yamaguchi T, Naitoh T, Katayose Y, et al.
Telomerase activity in pancreatic juice differentiates pancreatic cancer from
chronic pancreatitis: a meta-analysis. Pancreatology. 2016;16:372–81.
Choi et al. BMC Cancer           (2019) 19:11 Page 12 of 12
